For the management of peripheral neuropathy of diverse etiologies, fixed-dose combination of vitamin B1 (100 mg), B6 (100 mg) and B12 (5000 mcg) is efficacious, well-tolerated, improves symptoms, and boosts quality of life.

This single-arm, prospective, multi-center, open-label, non-interventional, observational study was carried out to examine the safety and efficacy of fixed-dose combination of high-dose vitamins for peripheral neuropathy in the Indonesian population.

This 12-week study comprised 411 participants who had mild to moderate peripheral neuropathy due to a variety of etiologies. A participant was deemed to have "completed" the study if all the study requirements were met up until visit 3 (1 month of therapy). Clinical outcomes at 12 weeks as well as procedural findings were described.

Within fourteen days of treatment, those who received a combination of vitamins B1, B6, and B12 illustrated remarkable improvements in their overall Total Symptom Score (TSS). Individual TSS components were successfully decreased from baseline to Visit 5 by the treatment.

At the conclusion of 12 weeks, all Visual Analogue Scale (VAS) parameters revealed a profound percentage decrease, while Quality of Life scores raised from the start of treatment to the end. Of 411 participants recruited in the study, 14 participants (3.4%) experienced at least one adverse event during the study period.

Treatment with a fixed-dose combination of vitamin B1, B6 and B12  is linked with remarkable improvements in TSS, VAS, and quality of life.